Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter

NEW YORK, October 1, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Covidien plc (NYSE: COV), Biogen Idec Inc. (NASDAQ: BIIB), Amgen Inc. (NASDAQ: AMGN), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6893-100free.

--
Covidien plc Research Reports
On September 25, 2014, Covidien plc (Covidien) announced that it will report its Q4 FY 2014 and full-year FY 2014 financial results on November 5, 2014. The Company will also host a conference call for investors on the same day at 8:30 a.m. ET. On average, analysts polled by Bloomberg Businessweek expect Covidien's Q4 FY 2014 earnings at $1.02 per share on revenue of $2.7 billion. Further, analysts project the Company's full-year FY 2014 EPS at $4.02. The full research reports on Covidien are available to download free of charge at:

http://www.analystsreview.com/Oct-01-2014/COV/report.pdf

--
Biogen Idec Inc. Research Reports
On September 25, 2014, Biogen Idec Inc. (Biogen) announced that it will report its Q3 2014 financial results on October 22, 2014, before the markets open. Following the financial results release, Biogen's management will discuss the performance at 9:00 am ET in a live webcast. On average, analysts polled by Bloomberg Businessweek expect the Company's Q3 2014 earnings at $3.45 per share on revenue of $2.5 billion. The full research reports on Biogen are available to download free of charge at:

http://www.analystsreview.com/Oct-01-2014/BIIB/report.pdf

--
Amgen Inc. Research Reports
On September 22, 2014, Amgen Inc. (Amgen) announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the blood and bone marrow. Amgen informed that its BiTE antibody constructs represent an innovative immunotherapy approach that helps the body's immune system target cancer cells. Blinatumomab, the first of the BiTE antibody constructs, has received both orphan drug designation and breakthrough therapy designation from the FDA for the treatment of ALL. "We look forward to working with regulatory authorities to make blinatumomab available for adult patients with acute lymphoblastic leukemia, who experience high relapse rates and have limited treatment options," said Sean E. Harper, M.D., Executive Vice President, R&D, Amgen. The full research reports on Amgen are available to download free of charge at:

http://www.analystsreview.com/Oct-01-2014/AMGN/report.pdf

--
Agios Pharmaceuticals, Inc. Research Reports
On September 26, 2014, Agios Pharmaceuticals, Inc. (Agios) announced that clinical data from a Phase I study of AG-120, an orally available, selective, potent inhibitor of the mutated IDH1 protein, will be highlighted in a late breaking oral presentation at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place from November 18 - 21, 2014, in Barcelona, Spain. "We believe IDH1 is an important target that has the potential to make a difference for patients with a broad range of hematologic and solid tumor cancers," said David Schenkein, M.D., CEO at Agios. Shares of the Company hit a fresh 52-week high and ended the session higher by 19.29% at $63.76, the same day. The full research reports on Agios are available to download free of charge at:

http://www.analystsreview.com/Oct-01-2014/AGIO/report.pdf

--
Baxter International Inc. Research Reports
On September 24, 2014, Baxter International Inc. (Baxter) and Merrimack Pharmaceuticals, Inc. (Merrimack) jointly announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as "nal-IRI." As per the agreement, Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the U.S. and Taiwan, and Merrimack retains commercialization rights in the U.S.; the rights in Taiwan are held separately. Merrimack would receive $100 million upfront payment from Baxter in Q3 2014. According to the announcement, Merrimack could also receive $120 million in regulatory milestone payments related to the first pancreatic cancer indication as these milestones are achieved; $280 million in development and regulatory milestone payments for a second pancreatic cancer indication; $220 million in future development and regulatory milestone payments; and $250 million in sales milestone payments, as well as tiered royalties on net sales of MM-398 in the licensed geographies. The full research reports on Baxter are available to download free of charge at:

http://www.analystsreview.com/Oct-01-2014/BAX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED